Trial Profile
Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Everolimus; Palbociclib; Trametinib
- Indications Solid tumours
- Focus Adverse reactions
- 14 Jun 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2025.
- 14 Jun 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2025.
- 14 Jun 2023 Status changed from recruiting to active, no longer recruiting.